HRP20221356T1 - Nova alkilirajuća sredstva - Google Patents
Nova alkilirajuća sredstva Download PDFInfo
- Publication number
- HRP20221356T1 HRP20221356T1 HRP20221356TT HRP20221356T HRP20221356T1 HR P20221356 T1 HRP20221356 T1 HR P20221356T1 HR P20221356T T HRP20221356T T HR P20221356TT HR P20221356 T HRP20221356 T HR P20221356T HR P20221356 T1 HRP20221356 T1 HR P20221356T1
- Authority
- HR
- Croatia
- Prior art keywords
- indol
- carbonyl
- thieno
- chloromethyl
- dihydro
- Prior art date
Links
- 229940100198 alkylating agent Drugs 0.000 title 1
- 239000002168 alkylating agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 3
- IIHLTOJHVNXPRZ-VZYDHVRKSA-N Cl.CN1CCN(CC1)C(=O)Oc1cc2N(C[C@@H](CCl)c2c2c(C)csc12)C(=O)c1cc2cc(NC(=O)c3cc4cc(N)ccc4[nH]3)ccc2[nH]1 Chemical compound Cl.CN1CCN(CC1)C(=O)Oc1cc2N(C[C@@H](CCl)c2c2c(C)csc12)C(=O)c1cc2cc(NC(=O)c3cc4cc(N)ccc4[nH]3)ccc2[nH]1 IIHLTOJHVNXPRZ-VZYDHVRKSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- IIHLTOJHVNXPRZ-FTBISJDPSA-N [(8r)-6-[5-[(5-amino-1h-indole-2-carbonyl)amino]-1h-indole-2-carbonyl]-8-(chloromethyl)-1-methyl-7,8-dihydrothieno[3,2-e]indol-4-yl] 4-methylpiperazine-1-carboxylate;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)OC(C=1SC=C(C)C=11)=CC2=C1[C@@H](CCl)CN2C(=O)C1=CC2=CC(NC(=O)C=3NC4=CC=C(N)C=C4C=3)=CC=C2N1 IIHLTOJHVNXPRZ-FTBISJDPSA-N 0.000 claims 1
- OGFLYTUKSKXWFD-VWLOTQADSA-N [(8r)-8-(chloromethyl)-1-methyl-6-[5-[[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1h-indole-2-carbonyl]amino]-1h-indole-2-carbonyl]-7,8-dihydrothieno[3,2-e]indol-4-yl] 4-methylpiperazine-1-carboxylate Chemical compound C1CN(C)CCN1C(=O)OC(C=1SC=C(C)C=11)=CC2=C1[C@@H](CCl)CN2C(=O)C1=CC2=CC(NC(=O)C=3NC4=CC=C(NC(=O)OC(C)(C)C)C=C4C=3)=CC=C2N1 OGFLYTUKSKXWFD-VWLOTQADSA-N 0.000 claims 1
- DLGMWIQPGAEPPC-SFHVURJKSA-N [(8r)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydrothieno[3,2-e]indol-6-yl]-[5-(2-pyrrolidin-1-ylethoxy)-1h-indol-2-yl]methanone Chemical compound C1([C@@H](CCl)C2)=C3C(C)=CSC3=C(O)C=C1N2C(=O)C(NC1=CC=2)=CC1=CC=2OCCN1CCCC1 DLGMWIQPGAEPPC-SFHVURJKSA-N 0.000 claims 1
- OGFLYTUKSKXWFD-RUZDIDTESA-N [(8s)-8-(chloromethyl)-1-methyl-6-[5-[[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1h-indole-2-carbonyl]amino]-1h-indole-2-carbonyl]-7,8-dihydrothieno[3,2-e]indol-4-yl] 4-methylpiperazine-1-carboxylate Chemical compound C1CN(C)CCN1C(=O)OC(C=1SC=C(C)C=11)=CC2=C1[C@H](CCl)CN2C(=O)C1=CC2=CC(NC(=O)C=3NC4=CC=C(NC(=O)OC(C)(C)C)C=C4C=3)=CC=C2N1 OGFLYTUKSKXWFD-RUZDIDTESA-N 0.000 claims 1
- DLGMWIQPGAEPPC-GOSISDBHSA-N [(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydrothieno[3,2-e]indol-6-yl]-[5-(2-pyrrolidin-1-ylethoxy)-1h-indol-2-yl]methanone Chemical compound C1([C@H](CCl)C2)=C3C(C)=CSC3=C(O)C=C1N2C(=O)C(NC1=CC=2)=CC1=CC=2OCCN1CCCC1 DLGMWIQPGAEPPC-GOSISDBHSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- VDJKHEMVOXNSNM-HSZRJFAPSA-N n-[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydrothieno[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]-5-(2-pyrrolidin-1-ylethoxy)-1h-indole-2-carboxamide Chemical compound C1([C@H](CCl)C2)=C3C(C)=CSC3=C(O)C=C1N2C(=O)C(NC1=CC=2)=CC1=CC=2NC(=O)C(NC1=CC=2)=CC1=CC=2OCCN1CCCC1 VDJKHEMVOXNSNM-HSZRJFAPSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- FGZKXOUQTSCULJ-HXUWFJFHSA-N tert-butyl n-[2-[[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydrothieno[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]carbamoyl]-1h-indol-5-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C2NC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5SC=C(C5=C4[C@H](CCl)C3)C)=CC2=C1 FGZKXOUQTSCULJ-HXUWFJFHSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163459 | 2012-04-05 | ||
| EP12176162 | 2012-07-12 | ||
| EP19184082.6A EP3587426B1 (en) | 2012-04-05 | 2013-03-28 | New alkylating agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221356T1 true HRP20221356T1 (hr) | 2022-12-23 |
Family
ID=48092927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221356TT HRP20221356T1 (hr) | 2012-04-05 | 2013-03-28 | Nova alkilirajuća sredstva |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9527863B2 (enExample) |
| EP (2) | EP3587426B1 (enExample) |
| JP (2) | JP6314128B2 (enExample) |
| CN (2) | CN107011358B (enExample) |
| DK (1) | DK2836494T3 (enExample) |
| ES (2) | ES2929759T3 (enExample) |
| HR (1) | HRP20221356T1 (enExample) |
| HU (1) | HUE060655T2 (enExample) |
| RU (1) | RU2632206C2 (enExample) |
| WO (1) | WO2013149948A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011358B (zh) | 2012-04-05 | 2020-05-05 | 内尔维阿诺医学科学有限公司 | 新的烷化剂 |
| RU2632199C2 (ru) * | 2012-04-05 | 2017-10-03 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Функционализированные производные тиеноиндола для лечения ракового заболевания |
| US10266547B2 (en) * | 2013-09-25 | 2019-04-23 | Nerviano Medical Sciences S.R.L. | Thieno[2,3-e]indole derivatives as new antitumor agents |
| KR102046862B1 (ko) | 2015-03-20 | 2019-11-20 | 화이자 인코포레이티드 | Cti 약물작용발생단을 함유하는 이관능성 세포독성제 |
| EP3325489B1 (en) | 2015-07-21 | 2019-11-13 | Nerviano Medical Sciences S.R.L. | Asymmetric process for the preparation of thieno-indoles derivatives |
| TWI660741B (zh) | 2015-11-03 | 2019-06-01 | 財團法人工業技術研究院 | 抗體藥物複合物及其製造方法 |
| KR102493853B1 (ko) * | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
| JP2023540585A (ja) * | 2020-09-09 | 2023-09-25 | クリヌヴェル （ユーケー） リミテッド | 色素性乾皮症を治療するためのピロリジン化合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3261684D1 (en) * | 1981-05-12 | 1985-02-07 | Ici Plc | Pyrrole derivatives |
| CA1238907A (en) * | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
| US5659022A (en) * | 1996-01-05 | 1997-08-19 | Epoch Pharmaceuticals, Inc. | Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids |
| JP3045706B1 (ja) * | 1998-09-14 | 2000-05-29 | 科学技術振興事業団 | Ｄｎａの特定塩基配列をアルキル化する化合物及びその合成法 |
| GB2344818A (en) | 1998-12-16 | 2000-06-21 | Pharmacia & Upjohn Spa | Anti-tumour thieno-indole derivatives |
| GB0015447D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US6989452B2 (en) * | 2001-05-31 | 2006-01-24 | Medarex, Inc. | Disulfide prodrugs and linkers and stabilizers useful therefor |
| JP2005502703A (ja) * | 2001-09-07 | 2005-01-27 | ザ スクリプス リサーチ インスティテュート | Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体 |
| WO2003026577A2 (en) * | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| CA2506080A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| US20070037739A1 (en) * | 2003-02-03 | 2007-02-15 | Medlogics Device Corporation | Compounds useful in coating stents to prevent and treat stenosis and restenosis |
| TW200526204A (en) * | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| US7282590B2 (en) | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
| US20050265925A1 (en) | 2004-04-21 | 2005-12-01 | Samuel Zalipsky | Releasable linkage and compositions containing same |
| RU2402548C2 (ru) * | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| MXPA06013413A (es) * | 2004-05-19 | 2007-01-23 | Medarex Inc | Enlazadores quimicos y conjugados de los mismos. |
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| BRPI0707426A2 (pt) * | 2006-02-02 | 2011-05-03 | Syntarga Bv | composto, conjugado, uso de um composto, composição farmacêutica, processo para preparar uma composição farmacêutica, e, métodos de tratamento de um mamìfero estando em necessidade do mesmo, e de tratamento ou prevenção de um tumor em um mamìfero |
| SI2120932T1 (sl) * | 2006-12-20 | 2014-09-30 | Nerviano Medical Sciences S.R.L. | Indazolni derivati kot kinazni inhibitorji za zdravljenje raka |
| MX2011000509A (es) | 2008-07-15 | 2011-04-05 | Genentech Inc | Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales. |
| RU2632199C2 (ru) * | 2012-04-05 | 2017-10-03 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Функционализированные производные тиеноиндола для лечения ракового заболевания |
| CN107011358B (zh) | 2012-04-05 | 2020-05-05 | 内尔维阿诺医学科学有限公司 | 新的烷化剂 |
-
2013
- 2013-03-28 CN CN201610942350.9A patent/CN107011358B/zh active Active
- 2013-03-28 CN CN201380016674.4A patent/CN104220442B/zh active Active
- 2013-03-28 EP EP19184082.6A patent/EP3587426B1/en active Active
- 2013-03-28 ES ES19184082T patent/ES2929759T3/es active Active
- 2013-03-28 DK DK13715931T patent/DK2836494T3/da active
- 2013-03-28 EP EP13715931.5A patent/EP2836494B1/en active Active
- 2013-03-28 ES ES13715931T patent/ES2755719T3/es active Active
- 2013-03-28 JP JP2015503835A patent/JP6314128B2/ja active Active
- 2013-03-28 HU HUE19184082A patent/HUE060655T2/hu unknown
- 2013-03-28 US US14/390,644 patent/US9527863B2/en active Active
- 2013-03-28 HR HRP20221356TT patent/HRP20221356T1/hr unknown
- 2013-03-28 RU RU2014143994A patent/RU2632206C2/ru active
- 2013-03-28 WO PCT/EP2013/056743 patent/WO2013149948A1/en not_active Ceased
-
2016
- 2016-11-23 US US15/359,703 patent/US10071074B2/en active Active
-
2017
- 2017-10-13 JP JP2017199656A patent/JP2018070599A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018070599A (ja) | 2018-05-10 |
| EP2836494B1 (en) | 2019-08-21 |
| EP3587426B1 (en) | 2022-08-10 |
| CN104220442A (zh) | 2014-12-17 |
| JP2015514101A (ja) | 2015-05-18 |
| DK2836494T3 (da) | 2019-11-11 |
| EP2836494A1 (en) | 2015-02-18 |
| CN104220442B (zh) | 2016-11-23 |
| EP3587426A1 (en) | 2020-01-01 |
| US9527863B2 (en) | 2016-12-27 |
| US20150051154A1 (en) | 2015-02-19 |
| HK1203957A1 (en) | 2015-11-06 |
| RU2632206C2 (ru) | 2017-10-03 |
| CN107011358B (zh) | 2020-05-05 |
| US10071074B2 (en) | 2018-09-11 |
| WO2013149948A1 (en) | 2013-10-10 |
| CN107011358A (zh) | 2017-08-04 |
| HUE060655T2 (hu) | 2023-04-28 |
| ES2755719T3 (es) | 2020-04-23 |
| US20170071907A1 (en) | 2017-03-16 |
| RU2014143994A (ru) | 2016-05-27 |
| ES2929759T3 (es) | 2022-12-01 |
| JP6314128B2 (ja) | 2018-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221356T1 (hr) | Nova alkilirajuća sredstva | |
| JP2014508804A5 (enExample) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20230854T1 (hr) | Fap-aktivirana terapeutska sredstva i s njima povezane uporabe | |
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| JP2017528524A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| IL228600B (en) | (Aralkylamino and heteroarylalkylamino alpha-converted) pyrimidinyl and 1,3,5-triazinyl benzaimidazoles, pharmaceutical preparations containing them and use of these compounds in the treatment of proliferative diseases | |
| WO2008083174A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
| IL244787B (en) | Polymorph c of n-((4,6-dimethyl-2 oxo-1,2-dihydropyridine-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl -4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide monohydrochloride, methods for its preparation, medical preparations containing it and its use | |
| JP2017528467A5 (enExample) | ||
| WO2009121063A3 (en) | Chemokine receptor modulators | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| WO2014105958A3 (en) | Fused pyrimidine compounds and use thereof | |
| HRP20201165T1 (hr) | Uporaba inhibitora ccr3 | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| WO2011160024A3 (en) | Compounds useful as antiviral agents, compositions, and methods of use | |
| MX2014003623A (es) | Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)-fenil]-n-metilacetamida con un intervalo de distribucion de tamaño de particula especifica y un intervalo de area superficial especifica para uso en formulaciones farmaceuticas. | |
| CA2806614C (en) | Combinatory cancer treatment | |
| WO2010098600A3 (en) | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same |